

CITATION REPORT

List of articles citing

Clinical pharmacokinetics of metformin

DOI: 10.2165/11534750-0000000000-000000
Clinical Pharmacokinetics, 2011, 50, 81-98.

Source: <https://exaly.com/paper-pdf/50147376/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
789	Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. 2011 , 43, 499-523		50
788	Pharmacokinetics of metformin in girls aged 9 years. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 735-8	6.2	9
787	Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. 2011 , 54, 3101-10		187
786	The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. 2011 , 21, 837-50		181
785	Intracerebroventricular administration of metformin inhibits ghrelin-induced Hypothalamic AMP-kinase signalling and food intake. 2012 , 96, 24-31		33
784	Current world literature. 2012 , 19, 142-7		
783	Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. 2012 , 30, 2593-600		196
782	Plasma membrane transporters in modern liver pharmacology. 2012 , 2012, 428139		14
781	Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. 2012 , 28, 1406-12		36
780	Pharmacology and safe prescribing of metformin. 2012 , 10, 597-602		3
779	Metformin pathways: pharmacokinetics and pharmacodynamics. 2012 , 22, 820-7		256
778	The effects of gastric bypass surgery on drug absorption and pharmacokinetics. 2012 , 8, 1505-19		38
777	Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. 2012 , 28, 1213-20		11
776	Saxagliptin plus metformin combination therapy. 2012 , 7, 151-164		2
775	Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. 2012 , 8, 383-94		9
774	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. 2012 , 33, 312-22		73
773	O-carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells. 2012 , 89, 1003-7		80

772	Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. 2012 , 16, 285-302	27
771	Cellular and molecular mechanisms of metformin: an overview. 2012 , 122, 253-70	1094
770	Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs. 2012 , 8, 1565-77	21
769	Fabrication of pH-sensitive graphene oxide drug supramolecular hydrogels as controlled release systems. 2012 , 22, 24856	115
768	Le parcours accidenté de la metformine: de l'ombre à la lumière !. 2012 , 6, 358-362	1
767	Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. 2012 , 13, 1377-84	11
766	Highlights from the latest articles in diabetes pharmacogenomics. 2012 , 13, 261-4	1
765	An electrostatically crosslinked chitosan hydrogel as a drug carrier. <i>Molecules</i> , 2012 , 17, 13704-11	4.8 31
764	Targeted Plasma Metabolite Profiling of Metformin in Healthy Korean Volunteers. 2012 , 20, 175	
763	Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. 2012 , 101, 1659-71	14
762	Pharmacokinetic study of mucoadhesive metformin pellets in rats. 2012 , 42, 133-137	1
761	Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. 2012 , 68, 961-8	32
760	Metformin therapy in patients with chronic kidney disease. 2012 , 14, 963-5	50
759	Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration. 2012 , 55, 443-9	51
758	Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. 2013 , 49, 1479-90	18
757	Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) protein. 2013 , 39, 17-22	25
756	A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. 2013 , 15, 1012-24	45
755	Metformin: an old drug with new potential. 2013 , 22, 1511-7	22

754	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. 2013 , 14, 25		26
753	The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. 2013 , 14, 22		58
752	Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. 2013 , 15, 571-80		55
751	Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 373-84	6.2	84
750	Population pharmacokinetic study of memantine: effects of clinical and genetic factors. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 211-23	6.2	34
749	The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. 2013 , 36, 733-46		54
748	Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics. 2013 , 45, 2007-11		50
747	Complications of diabetes therapy. 2013 , 42, 947-70		16
746	Transporters and drug-drug interactions: important determinants of drug disposition and effects. 2013 , 65, 944-66		391
745	Repositioning metformin for cancer prevention and treatment. 2013 , 24, 469-80		215
744	Efficacy and safety of Jentaduetto [®] (linagliptin plus metformin). 2013 , 12, 275-89		6
743	5'-AMP-activated protein kinase-activating transcription factor 1 cascade modulates human monocyte-derived macrophages to atheroprotective functions in response to heme or metformin. 2013 , 33, 2470-80		33
742	Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. 2013 , 34, 126-35		117
741	Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. 2013 , 15, 189-91		77
740	Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin. 2013 , 42, 250-6		26
739	Mechanism of metformin: inhibition of DNA damage and proliferative activity in <i>Drosophila</i> midgut stem cell. 2013 , 134, 381-90		46
738	Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. 2013 , 61, 971-80		29
737	Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF- κ B activation. 2013 , 12, 489-98		289

736	Cucurbit[7]uril Host-Guest Complexes with Biguanidinium Cations in Aqueous Solution. 2013 , 2013, 2573-2582	10
735	Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. 2013 , 39, 179-90	115
734	Case Studies in Electrolyte and Acid-Base Disorders. 2013 , 327-361	
733	Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. 2013 , 51, 444-7	31
732	Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. 2013 , 9, 529-50	64
731	Metformin use in chronic kidney disease: new evidence to guide dosing. 2013 , 106, 1059-61	10
730	Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. 2013 , 41, 1967-71	22
729	Update on the protective molecular pathways improving pancreatic beta-cell dysfunction. 2013 , 2013, 750540	18
728	Pharmacogenetics of oral antidiabetic drugs. 2013 , 2013, 686315	28
727	Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. 2013 , 12, 2847-56	65
726	Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. 2013 , 6, 801-10	57
725	A capillary zone electrophoretic method for the determination of hypoglycemics as adulterants in herbal formulations used for the treatment of diabetes. 2013 , 5, 2126	9
724	Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. 2013 , 76, 787-96	54
723	Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. 2013 , 22, 1027-35	37
722	Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. 2013 , 102, 3407-17	49
721	Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. 2013 , 9, 363-77	9
720	A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. 2013 , 5, 252-63	19
719	The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 186-94	6.1 143

718	Counterion Affects Interaction with Interfaces: The Antidiabetic Drugs Metformin and Decavanadate. 2013 , 2013, 1859-1868	34
717	Pharmacogenetics and personalized treatment of type 2 diabetes. 2013 , 23, 154-71	26
716	Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. 2013 , 3, 1051-75	26
715	Two weeks of metformin treatment enhances mitochondrial respiration in skeletal muscle of AMPK kinase dead but not wild type mice. 2013 , 8, e53533	39
714	Metformin. 2013 , 1-2	
713	High-performance thin-layer chromatographic assay of metformin in urine using ion-pair solid-phase extraction: Application for bioavailability and bioequivalence study of new microbeads controlled release formulation. 2014 , 27, 377-384	7
712	Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. 2014 , 3, e02242	628
711	In vitro and in vivo biological evaluation of O-carboxymethyl chitosan encapsulated metformin nanoparticles for pancreatic cancer therapy. 2014 , 31, 3361-70	26
710	Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. 2014 , 289, 27055-27064	49
709	Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. 2014 , 42, 1174-9	29
708	Cardiovascular impact of drugs used in the treatment of diabetes. 2014 , 5, 245-68	46
707	Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models. 2014 , 5, 232	11
706	The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment. 2014 , 2014, 934729	11
705	Non-alcoholic fatty liver disease in patients with diabetes mellitus. 2014 , 9, 503-514	
704	Pharmacological treatment of diabetes in older people. 2014 , 16, 1192-203	35
703	Something old, something new and something very old: drugs for treating type 2 diabetes. 2014 , 171, 2940-50	11
702	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. 2014 , 148, 81-90	58
701	Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene. 2014 , 5, 736-44	21

700	Metformin in patients with type 2 diabetes and kidney disease: a systematic review. 2014 , 312, 2668-75	355
699	Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study. 2014 , 36, 211-7	18
698	Guanylurea metformium double salt of decavanadate, (HGU ⁺) ₄ (HMet ⁺) ₂ (V10O ₂₈) ₁₂ ·2H ₂ O. 2014 , 420, 85-91	15
697	Large volume sample stacking for rapid and sensitive determination of antidiabetic drug metformin in human urine and serum by capillary electrophoresis with contactless conductivity detection. 2014 , 1345, 207-11	27
696	Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study. 2014 , 34, 36-45	24
695	Establishing postprandial bio-equivalency and IVIVC for generic metformin sustained release small sized tablets. 2014 , 44, 197-204	2
694	A prospective analysis of co-processed non-ionic surfactants in enhancing permeability of a model hydrophilic drug. 2014 , 15, 339-53	17
693	Type II Diabetes, Metformin Use, and Colorectal Neoplasia: Mechanisms of Action and Implications for Future Research. 2014 , 10, 105-113	3
692	An update on the pharmacogenomics of metformin: progress, problems and potential. 2014 , 15, 529-39	42
691	Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. 2014 , 52, 129-35	72
690	Two weeks of metformin treatment induces AMPK-dependent enhancement of insulin-stimulated glucose uptake in mouse soleus muscle. 2014 , 306, E1099-109	47
689	Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions. 2014 , 37, 903-19	19
688	Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells. 2014 , 21, 597-603	31
687	Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 837-47	6.2 45
686	First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. 2014 , 20, 656-69	93
685	Nierinsufficiëntie en medicatie. 2014 , 30, 54-60	
684	Metformin, cancer and glucose metabolism. 2014 , 21, R461-71	65
683	Pharmacokinetic interactions between topiramate and pioglitazone and metformin. 2014 , 108, 1519-32	11

682	Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). <i>Clinical Pharmacokinetics</i> , 2014 , 53, 1083-114	6.2	40
681	Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study. 2014 , 36, 1171-81		10
680	Metformin in chronic kidney disease: time for a rethink. 2014 , 34, 353-7		20
679	Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. 2014 , 10, 839-57		35
678	Interaction of a biguanide compound with membrane model interface systems: probing the properties of antimalaria and antidiabetic compounds. 2014 , 30, 8697-706		20
677	Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 370-9	6.1	46
676	Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. 2014 , 33, 41		47
675	Pharmacokinetics Study of Metformin [Mathematical Modelling and Simulation. 2014 , 9, 151-158		1
674	Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. 2014 , 37, 2218-24		102
673	Personalising metformin therapy: a clinician's perspective. 2014 , 2, 442-4		7
672	Personalized medicine in Type 2 Diabetes. 2014 , 4, 8		23
671	DrugDrug Interaction: From Bench to Drug Label. 2015 , 139-178		
670	Drug-drug interactions in pharmacologic management of gastroparesis. 2015 , 27, 1528-41		16
669	Metformin effects on biochemical recurrence and metabolic signaling in the prostate. 2015 , 75, 1694-703		7
668	Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. 2015 , 4, 121-9		19
667	Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes. 2015 , 25, 475-84		5
666	Metformin for cancer and aging prevention: is it a time to make the long story short?. 2015 , 6, 39398-407		48
665	Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?. 2015 , 2015, 415149		15

664	Metformin-associated lactic acidosis. 2015 , 349, 263-7	28
663	Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. 2015 , 71, 691-697	36
662	Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females. 2015 , 11, 759-70	1
661	Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup. 2015 , 43, 1716-30	124
660	Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels. 2015 , 9, 808-14	42
659	Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. 2015 , 64, 3305-13	26
658	Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. 2015 , 33, 744-50	20
657	Metformin and metabolic diseases: a focus on hepatic aspects. 2015 , 9, 173-86	56
656	Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. 2015 , 8, 197-207	41
655	Quantitative in vitro to in vivo extrapolation of tissues toxicity. 2015 , 30, 203-16	18
654	Development and validation of fast and simple flow injection analysis-tandem mass spectrometry (FIA-MS/MS) for the determination of metformin in dog serum. 2015 , 107, 229-35	26
653	The metabolic state of cancer stem cells-a valid target for cancer therapy?. 2015 , 79, 264-8	21
652	Vanadium phosphatase complexes: Phosphatase inhibitors favor the trigonal bipyramidal transition state geometries. 2015 , 301-302, 163-199	89
651	A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes. 2015 , 71, 59-63	15
650	Should pharmacokinetic safety challenges prevent metformin use in patients with cancer?. 2015 , 28, 48-9	2
649	Characterisation of selected active agents regarding pKa values, solubility concentrations and pH profiles by SiriusT3. 2015 , 92, 155-70	38
648	SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. 2015 , 109, 57-63	33
647	Role of organic cation transporters in drug-drug interaction. 2015 , 11, 1619-33	64

646	Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. 2015 , 88, 75-83	62
645	Early treatment with metformin induces resistance against tumor growth in adult rats. 2015 , 16, 958-64	3
644	Analysis of metformin, sitagliptin and creatinine in human dried blood spots. 2015 , 997, 218-28	26
643	Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. 2016 , 54, 1-9	16
642	Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. 2015 , 354, 225-9	10
641	Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin. 2015 , 53, 147-53	5
640	Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. 2015 , 3, 605-14	96
639	Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. 2015 , 79, 298-306	24
638	Personalized medicine in diabetes mellitus: current opportunities and future prospects. 2015 , 1346, 45-56	44
637	Metformin for the management of gestational diabetes mellitus. 2015 , 55, 303-8	8
636	Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). 2015 , 128, 63-74	56
635	Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels. 2015 , 44, 218-24	19
634	Genetics of drug response in type 2 diabetes. 2015 , 15, 43	7
633	A Comprehensive Review of Drug-Drug Interactions with Metformin. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 811-24	6.2 43
632	Metformin and other biguanides: pharmacology and therapeutic usage. 2015 , 641-656	2
631	The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome. 2015 , 44, 1-10	34
630	Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. 2015 , 21, 506-11	242
629	Biocompatible polymeric nanocomplexes as an intracellular stimuli-sensitive prodrug for type-2 diabetes combination therapy. 2015 , 73, 149-59	19

628	Preventing Allograft Rejection by Targeting Immune Metabolism. 2015 , 13, 760-770	122
627	Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. 2015 , 58, 2494-502	22
626	The Ethics Around Drug Labels and Generic Medicines. 2015 , 49, 348-351	1
625	Metformin and cancer: Between the bioenergetic disturbances and the antifolate activity. 2015 , 101, 102-8	39
624	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. 2016 , 39, 198-205	182
623	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). 2015 , 12, 4301-10	61
622	Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition. 2015 , 213, 171-80	41
621	The effect of metformin on glucose homeostasis during moderate exercise. 2015 , 38, 293-301	17
620	Inhibitory effect of atenolol on urinary excretion of metformin via down-regulating multidrug and toxin extrusion protein 1 (rMate1) expression in the kidney of rats. 2015 , 68, 18-26	13
619	Analyses of Biguanides and Related Compounds in Biological and Environmental Samples by HPLC. 2015 , 38, 303-321	3
618	Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?. 2015 , 277, 235-247	22
617	Metformin and other antidiabetic agents in renal failure patients. 2015 , 87, 308-22	86
616	The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. 2015 , 79, 617-23	6
615	Metformin-loaded BSA nanoparticles in cancer therapy: a new perspective for an old antidiabetic drug. 2015 , 71, 627-36	25
614	Metformin aggravates immune-mediated liver injury in mice. 2015 , 89, 437-50	21
613	Practical combination therapy based on pathophysiology of type 2 diabetes. 2016 , 9, 355-369	14
612	High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. 2016 , 7, 9102-17	22
611	The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. 2016 , 2016, 4350712	25

610	Influence of Sodium Alginate on Hypoglycemic Activity of Metformin Hydrochloride in the Microspheres Obtained by the Spray Drying. 2016 , 2016, 1-12	11
609	Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. 2016 , 10, 2525-34	9
608	Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. 2016 , 10, 1411-8	2
607	Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. 2016 , 9, 17-29	11
606	The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects. 2016 , 72, 400-7	61
605	Limited sampling strategy for determining metformin area under the plasma concentration-time curve. 2016 , 82, 1002-10	7
604	The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. 2016 , 132, 244-248	4
603	Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. 2016 , 5, 118-30	9
602	Early Discontinuation of Metformin in Individuals Treated with Inhibitors of Transporters of Metformin. 2016 , 118, 487-95	6
601	NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo. 2016 , 9, 91	15
600	Uromastix acanthinura as a natural treatment in a mouse model of type 2 diabetes. 2016 , 63, 13-18	
599	Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study. 2016 , 95, e3527	21
598	Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats. 2016 , 44, 1184-92	21
597	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. 2016 , 59, 1645-54	67
596	Uromastix acanthinura as a natural treatment in a mouse model of type 2 diabetes. 2016 , 63, 13-8	1
595	Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?. 2016 , 23, 569-70	103
594	Pharmacogenetics of Metformin. 2016 , 463-481	
593	Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. 2016 , 12, 337-46	36

592	Combinational strategies of metformin and chemotherapy in cancers. 2016 , 78, 13-26		81
591	The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers. 2016 , 72, 725-30		7
590	Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. 2016 , 56 Suppl 7, S23-39		63
589	In Vivo Imaging of Human ¹¹ C-Metformin in Peripheral Organs: Dosimetry, Biodistribution, and Kinetic Analyses. 2016 , 57, 1920-1926		72
588	Metformin-related lactic acidosis: is it a myth or an underestimated reality?. 2016 , 38, 1560-1565		21
587	On the unexpected reproductive impacts of metformin: A need for support and new directions for the evaluation of the impacts of pharmaceuticals in the environment. 2016 , 165, 570-574		8
586	Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. 2016 , 14, 65		44
585	The radioprotective effect of metformin against cytotoxicity and genotoxicity induced by ionizing radiation in cultured human blood lymphocytes. 2016 , 809, 24-32		39
584	Cette metformine, si connue. Si m̃onnue pour ses taux th̃apeutiques□ 2016 , 10, 471-474		
583	A comparative study between melt granulation/compression and hot melt extrusion/injection molding for the manufacturing of oral sustained release thermoplastic polyurethane matrices. <i>International Journal of Pharmaceutics</i> , 2016 , 513, 602-611	6.5	20
582	Metformin: From Research to Clinical Practice. 2016 , 45, 819-843		21
581	Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol. 2016 , 60, 7105-7114		18
580	Voltammetric and capillary electrophoretic study of scavenger kinetics of methylglyoxal by antidiabetic biguanide drugs. 2016 , 777, 26-32		5
579	Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models. 2016 , 56 Suppl 7, S99-S109		29
578	Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries. 2016 , 5, 40-51		3
577	Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. 2016 , 33, 105-10		26
576	Comments on Niemuth, N.J. and Klaper, R.D. 2015. Emerging wastewater contaminant metformin causes intersex and reduced fecundity in fish. <i>Chemosphere</i> 135, 38-45. 2016 , 165, 566-569		4
575	Extreme Basicity of Biguanide Drugs in Aqueous Solutions: Ion Transfer Voltammetry and DFT Calculations. 2016 , 120, 7344-50		16

574	Reply. 2016 , 68, 3043		1
573	Ion-pair vortex assisted liquid-liquid microextraction with back extraction coupled with high performance liquid chromatography-UV for the determination of metformin in plasma. 2016 , 161, 398-404		19
572	A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 100, 537-547	6.1	10
571	Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. 2016 , 111, 237-246		64
570	Environment Dictates Dependence on Mitochondrial Complex I for NAD ⁺ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. 2016 , 24, 716-727		185
569	Renal drug transporters and their significance in drug-drug interactions. <i>Acta Pharmaceutica Sinica B</i> , 2016 , 6, 363-373	15.5	90
568	The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. 2016 , 7, 12308		122
567	The Application of Genomics in Diabetes: Barriers to Discovery and Implementation. 2016 , 39, 1858-1869		21
566	Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients. 2016 , 175, 531-540		16
565	Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin. 2016 , 39, 2022-2027		4
564	Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. 2016 , 95, e4526		46
563	Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects. 2016 , 56, 1104-10		6
562	Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?. 2016 , 39, 1287-91		23
561	Potential Upstream Strategies for the Mitigation of Pharmaceuticals in the Aquatic Environment: a Brief Review. 2016 , 3, 153-60		15
560	Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. 2016 , 31, 385-388		15
559	Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. 2016 , 5, 27-39		17
558	Measuring the biological effect of presurgical metformin treatment in endometrial cancer. 2016 , 114, 281-9		64
557	Mechanism of Metformin: A Tale of Two Sites. 2016 , 39, 187-9		89

556	Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. 2016 , 88, 70-82		67
555	Metformin and the gastrointestinal tract. 2016 , 59, 426-35		330
554	Will delayed release metformin provide better management of diabetes type 2?. 2016 , 17, 627-30		10
553	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ~240-Fold Higher Drug Concentration in Urine than Serum. 2016 , 15, 430-8		12
552	Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males. 2016 , 46, 703-8		4
551	The Effect of Exercise with or Without Metformin on Glucose Profiles in Type 2 Diabetes: A Pilot Study. 2016 , 40, 173-7		17
550	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 711-21	6.2	37
549	Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride. 2016 , 23, 2796-2805		38
548	Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 507-24	6.2	44
547	S.A.M. and Breast Cancer Focus on Metformin and Other Integrative Metformin-Mimic Medicines: The Real Natural Options. 2016 , 195-223		
546	Mathematical Model-Based Accelerated Development of Extended-release Metformin Hydrochloride Tablet Formulation. 2016 , 17, 1007-13		12
545	Metformin-associated lactic acidosis: Current perspectives on causes and risk. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 20-9	12.7	246
544	Therapeutic Concentrations of Metformin: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 439-59	6.2	93
543	Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats. 2016 , 41, 559-65		12
542	Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. 2017 , 219, 138-151		67
541	Pharmacokinetics of metformin in the rat: assessment of the effect of hyperlipidemia and evidence for its metabolism to guanylurea. 2017 , 95, 530-538		8
540	A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. 2017 , 14, 164-180		34
539	The emerging role of metformin in gestational diabetes mellitus. 2017 , 19, 765-772		23

538	Treatment of Metformin Intoxication Complicated by Lactic Acidosis and Acute Kidney Injury: The Role of Prolonged Intermittent Hemodialysis. 2017 , 70, 290-296		14
537	Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. 2017 , 19, 1078-1087		16
536	Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms. 2017 , 7, 20160109		17
535	Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression. 2017 , 10, 198-207		27
534	Metformin represses glucose starvation induced autophagic response in microvascular endothelial cells and promotes cell death. 2017 , 132, 118-132		27
533	Controlled release of metformin from chitosan-based nanocomposite films containing mesoporous MCM-41 nanoparticles as novel drug delivery systems. 2017 , 501, 60-76		94
532	Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm. 2017 , 19, 1502-1512		62
531	Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies. 2017 , 75, 311-317		16
530	Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 1391-1401	6.2	26
529	GIT Anatomy and Physiology and Drug Oral Bioavailability: Impact of Species Differences. 2017 , 35-76		1
528	Transporters Involved in Metformin Pharmacokinetics and Treatment Response. 2017 , 106, 2245-2250		72
527	Metformin-associated lactic acidosis: Moving towards a new paradigm?. 2017 , 19, 1499-1501		10
526	Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state. 2017 , 6, 737-747		15
525	Progress in the application and mechanism of metformin in treating non-small cell lung cancer. 2017 , 13, 2873-2880		14
524	Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. 2017 , 135, 147-153		18
523	A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. 2017 , 73, 981-990		11
522	New prodrugs of metformin do not influence the overall haemostasis potential and integrity of the erythrocyte membrane. 2017 , 811, 208-221		14
521	Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla. 2017 , 34, 2614-2627		135

520	Metformin Synergizes With Conventional and Adjuvant Analgesic Drugs to Reduce Inflammatory Hyperalgesia in Rats. 2017 , 124, 1317-1329		7
519	Modulatory effects of metformin on mutagenicity and epithelial tumor incidence in doxorubicin-treated <i>Drosophila melanogaster</i> . 2017 , 106, 283-291		11
518	Addendum Regarding Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration [Am J Kidney Dis. 2016;68[6]:990-992]. 2017 , 69, 870		1
517	Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations. 2017 , 42, 973-980		12
516	Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations. 2017 , 47, 151-161		5
515	Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. 2017 , 2, 705-712		14
514	The Influence of Proton-Pump Inhibitors on Glycemic Control: A Systematic Review of the Literature and a Meta-Analysis. 2017 , 41, 351-361		6
513	Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 841-848	6.1	61
512	Toxicokinetics of Metformin During Hemodialysis. 2017 , 2, 759-762		8
511	Understanding and overcoming metformin gastrointestinal intolerance. 2017 , 19, 473-481		83
510	New insights into the anti-diabetic actions of metformin: from the liver to the gut. 2017 , 11, 157-166		30
509	Acidosis láctica por metformina: reporte de caso. 2017 , 45, 353-359		2
508	Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. 2017 , 5, e00357		25
507	Metformin-related lactic acidosis: Case report. 2017 , 45, 353-359		
506	Pharmacokinetics and oral bioavailability of metformin hydrochloride in healthy mixed-breed dogs. 2017 , 78, 1193-1199		6
505	Metformin-Associated Lactic Acidosis Undergoing Renal Replacement Therapy in Intensive Care Units: A Five-Million Population-Based Study in the North-West of Italy. 2017 , 44, 198-205		25
504	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. 2017 , 16, 1121-1132		12
503	The pharmacogenetics of metformin. 2017 , 60, 1648-1655		46

502	The mechanisms of action of metformin. 2017 , 60, 1577-1585		870
501	Metformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress. <i>Scientific Reports</i> , 2017 , 7, 5690	4.9	36
500	Association Between Stroke Risk and Metformin Use in Hemodialysis Patients With Diabetes Mellitus: A Nested Case-Control Study. 2017 , 6,		12
499	Reactions between methylglyoxal and its scavengers in-vivo appear to be catalyzed enzymatically. 2017 , 109, 153-155		4
498	Could metformin be used in patients with advanced chronic kidney disease?. 2017 , 19, 302-303		0
497	Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers. 2017 , 6, 408-419		3
496	Carnauba wax as a promising excipient in melt granulation targeting the preparation of mini-tablets for sustained release of highly soluble drugs. 2017 , 70, 250-257		18
495	Could metformin be used in patients with diabetes and advanced chronic kidney disease?. 2017 , 19, 156-161		4
494	The Phantom of Metformin-Induced Lactic Acidosis in End-Stage Renal Disease Patients: Time to Reconsider with Peritoneal Dialysis Treatment. 2017 , 37, 56-62		5
493	Pharmacogenetic Factors That Affect Drug Metabolism and Efficacy in Type 2 Diabetes Mellitus. 2017 , 157-179		1
492	Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. 2017 , 57, 219-229		13
491	Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. 2017 , 31, 69-77		31
490	Nephroprotective Effects of Metformin in Diabetic Nephropathy. 2017 , 232, 731-742		82
489	Treatment with AICAR inhibits blastocyst development, trophectoderm differentiation and tight junction formation and function in mice. 2017 , 23, 771-785		12
488	Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials. 2017 , 8, 57733-57754		34
487	Metformin-related lactic acidosis: Case report?. 2017 , 45, 353-359		1
486	The Influence of Chitosan Cross-linking on the Properties of Alginate Microparticles with Metformin Hydrochloride-In Vitro and In Vivo Evaluation. <i>Molecules</i> , 2017 , 22,	4.8	15
485	rs2075604 Polymorphism Is Associated with Metformin Efficacy in Chinese Type 2 Diabetes Mellitus. 2017 , 2017, 3402808		4

484	The desert gerbil <i>Psammomys obesus</i> as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact of mitochondrial redox state. 2017 , 12, e0172053	12
483	Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis. 2017 , 11, e0005370	10
482	Herkennen hypoglykemieën bij oudere diabetespatiënten is lastig. 2017 , 60, 517-519	
481	Genetic polymorphisms of multidrug and toxin extrusion proteins (MATE1 and MATE2) in South Indian population. 2017 , 7, 25-30	3
480	Drug Interactions of Metformin Involving Drug Transporter Proteins. 2017 , 7, 501-505	22
479	Metformin and Chronic Renal Disease: Proposal for a Territorial Therapeutic Diagnostic Path. 2017 , 29, 90-94	
478	Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. 2018 , 109, 1066-1074	18
477	Houttuynia cordata extract increased systemic exposure and liver concentrations of metformin through OCTs and MATEs in rats. 2018 , 32, 1004-1013	9
476	Pharmacokinetics of metformin in patients with gastrointestinal intolerance. 2018 , 20, 1593-1601	20
475	Genetic Contributions and Personalized Medicine. 2018 , 3-16	0
474	Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects. <i>Scientific Reports</i> , 2018 , 8, 3929	4-9 16
473	Severe lactic acidosis and hypoglycemia due to acute metformin intoxication in a dog. 2018 , 28, 274-278	
472	Metformin: Prevention of genomic instability and cancer: A review. 2018 , 827, 1-8	43
471	Multifunctional Nanoflowers for Simultaneous Multimodal Imaging and High-Sensitivity Chemo-Photothermal Treatment. 2018 , 29, 559-570	31
470	Metformin potentiates cognitive and antidepressant effects of fluoxetine in rats exposed to chronic restraint stress and high fat diet: potential involvement of hippocampal c-Jun repression. 2018 , 391, 407-422	20
469	Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort. 2018 , 84, 987-996	10
468	A reappraisal on metformin. 2018 , 92, 324-332	41
467	Application of matrix-assisted laser desorption/ionization mass spectrometry imaging in combination with LC-MS in pharmacokinetic study of metformin. 2018 , 10, 71-81	2

466	Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. 2018 , 41, 547-553	75
465	'Massive' metformin overdose. 2018 , 84, 2923-2927	12
464	SIRT3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells. 2018 , 367, 137-149	33
463	Treatment with Oral Drugs. 2018 , 1-44	
462	Does poor fetal growth influence the extent of fetal exposure to maternal medications?. 2018 , 130, 74-84	8
461	Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. 2018 , 43, 69-80	21
460	A phase Ib study of everolimus combined with metformin for patients with advanced cancer. 2018 , 36, 53-61	13
459	Concentration-dependent metabolic effects of metformin in healthy and Fanconi anemia lymphoblast cells. 2018 , 233, 1736-1751	16
458	Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus. 2017 , 9, 587	21
457	The inhibitory effects of nano-encapsulated metformin on growth and hTERT expression in breast cancer cells. 2018 , 43, 19-26	36
456	Metformin: A Review of Characteristics, Properties, Analytical Methods and Impact in the Green Chemistry. 2018 , 48, 66-72	11
455	Risk of Metformin-Associated Lactic Acidosis (MALA) in Patients After Gastric Bypass Surgery. 2018 , 28, 1080-1085	3
454	Metformin. 2018 ,	
453	Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans. 2018 , 26, 79-85	7
452	Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review. 2018 , 97, e11349	28
451	Does the antidiabetic drug metformin affect embryo development and the health of brown trout (f.)?. 2018 , 30, 48	12
450	Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients. 2018 , 33, 175-185	7
449	Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults. 2018 , 26, 25-31	4

448	Metformin in Reproductive Biology. 2018 , 9, 675	34
447	In Search of a Breakthrough Therapy for Glioblastoma Multiforme. 2018 , 1, 292-310	6
446	Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. 2018 , 2, 242-245	4
445	Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. 2018 , 13, e0203946	20
444	Oral Agents for the Treatment of Gestational Diabetes. 2018 , 18, 119	14
443	Pleiotropic Effects of Metformin on Cancer. 2018 , 19,	41
442	Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. 2018 , 13, e0204317	60
441	Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium. 2018 , 115, 10475-10480	63
440	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. 2018 , 19, 1903-1914	10
439	Treatment with Oral Drugs. 2018 , 527-569	
438	La metformine dans l'insuffisance rénale : place (enfin) aux faits. 2018 , 12, 326-332	
437	Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. 2018 , 48, 87-98	54
436	Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?. 2018 , 14, 1149-1159	8
435	Antidiabetic Biguanides Radiosensitize Hypoxic Colorectal Cancer Cells Through a Decrease in Oxygen Consumption. 2018 , 9, 1073	18
434	Pharmacokinetics of metformin in patients with chronic kidney disease stage 4 and metformin-naïve type 2 diabetes. 2018 , 6, e00424	5
433	Complex decisions in the use of extracorporeal treatments in acute metformin overdose: which modality, when and how to measure the effect. 2018 , 84, 2689-2691	2
432	Metformin from mother to unborn child - Are there unwarranted effects?. 2018 , 35, 394-404	23
431	Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. 2018 , 9, 10135-10146	

430	Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use. 2018 , 63, 2840-2852		10
429	A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT. 2018 , 19, 715-726		8
428	Patient-factors associated with metformin steady-state levels in type 2 diabetes mellitus with therapeutic dosage. 2018 , 12, 42-47		4
427	Fatal Case of Metformin-Associated Lactic Acidosis Associated With Temporary Ileostomy: A Case Report. 2018 , 45, 364-365		1
426	Pharmacogenetics of Antidiabetic Drugs. 2018 , 83, 361-389		9
425	Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles. 2018 , 13, 1085-1095		75
424	Involvement of organic cation transporter 2 in the metformin-associated increased lactate levels caused by contrast-induced nephropathy. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 106, 1760-1766	7.5	4
423	The development and validation of a LC-MS/MS method for the quantitation of metformin, rifampicin and isoniazid in rat plasma using HILIC chromatography. 2018 , 1095, 127-137		9
422	Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens. 2018 , 13, 1254-1263		27
421	Nanocomposites in Controlled & Targeted Drug Delivery Systems. 2018 , 20, 27-45		7
420	The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. 2018 , 17, 837-848		3
419	Metformin and Autoimmunity: A "New Deal" of an Old Drug. 2018 , 9, 1236		85
418	Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications. 2018 , 50, 1391-1406		11
417	Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy. 2018 , 94, 1125-1131		24
416	A preclinical overview of metformin for the treatment of type 2 diabetes. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 106, 1227-1235	7.5	36
415	Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. 2018 , 20, 365-374		15
414	Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. 2018 , 24, 1395-1406		113
413	Recurrent hypoglycemia secondary to metformin toxicity in the absence of co-ingestions: a case report. 2018 , 12, 223		6

412	Co-delivery of Metformin and Paclitaxel Via Folate-Modified pH-Sensitive Micelles for Enhanced Anti-tumor Efficacy. 2018 , 19, 2395-2406		13
411	Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery. 2018 , 11, 5584-5595		31
410	A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study. 2018 , 13, e0191258		10
409	TKTL1 modulates the response of paclitaxel-resistant human ovarian cancer cells to paclitaxel. 2018 , 503, 572-579		7
408	Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes. 2018 , 19, 905-911		7
407	Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. 2019 , 15, 569-589	183	
406	Recent advances and perspectives in next generation sequencing application to the genetic research of type 2 diabetes. 2019 , 10, 376-395		8
405	The Association between Metformin Therapy and Lactic Acidosis. 2019 , 42, 1449-1469		13
404	New Targeted Treatments for Fragile X Syndrome. 2019 , 15, 251-258		16
403	A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation. 2019 , 175, 112754		5
402	A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. 2019 , 33, e4663		8
401	Mitochondrial targets of metformin-Are they physiologically relevant?. 2019 , 45, 703-711		16
400	A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 1398-1407	6.1	14
399	Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. 2019 , 40, 176-187		1
398	Visual and spectrophotometric detection of metformin based on the host-guest molecular recognition of cucurbit[6]uril-modified silver nanoparticles. 2019 , 411, 7293-7301		10
397	Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety. 2019 , 10, 1032		4
396	Pharmacology of metformin - An update. 2019 , 865, 172782		21
395	Metformin lactic acidosis: Should we still be afraid?. 2019 , 157, 107879		10

394	Drug-drug interactions when treating HIV-related metabolic disorders. 2019 , 15, 787-802	4
393	Metformin and Aging: A Review. 2019 , 65, 581-590	57
392	Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". 2019 , 29, 1127-1150	38
391	Development of USP Apparatus 3 Dissolution Method with IVIVC for Extended Release Tablets of Metformin Hydrochloride and Development of a Generic Formulation. 2019 , 67, 23-31	3
390	Management of diabetes mellitus in patients undergoing liver transplantation. 2019 , 141, 556-573	14
389	Metformin inhibits A β -induced apoptotic cell death in SH-SY5Y cells. 2019 , 125, 439-449	8
388	Assessing the trend of diabetes mellitus by analyzing metformin as a biomarker in wastewater. 2019 , 688, 281-287	22
387	Near-infrared light activatable hydrogels for metformin delivery. 2019 , 11, 15810-15820	17
386	Allele Frequency of Met420del Metformin Main Transporter Encoding Gene among Javanese-Indonesian Population. 2019 , 7, 378-383	1
385	Biodistribution of [¹⁴ C]-Metformin and mRNA Expression of Placentae Metformin Transporters in the Pregnant Chinchilla. 2019 , 2019, 9787340	2
384	Metformin Promotes Anxiolytic and Antidepressant-Like Responses in Insulin-Resistant Mice by Decreasing Circulating Branched-Chain Amino Acids. 2019 , 39, 5935-5948	50
383	Metformin: time to review its role and safety in chronic kidney disease. 2019 , 211, 37-42	13
382	A de novo formulation of metformin using chitosan-based nanomicelles for potential diabetes therapy. 2019 , 136, 48037	8
381	Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets. 2019 , 13, 1623-1632	4
380	Role of Mitochondria in the Mechanism(s) of Action of Metformin. 2019 , 10, 294	112
379	The protective effects of a novel polysaccharide from <i>Lentinus edodes</i> mycelia on islet β (INS-1) cells damaged by glucose and its transportation mechanism with human serum albumin. 2019 , 134, 344-353	11
378	Effects of naringenin on renal expression of organic cation transporter 1 and 2 proteins and metformin disposition in diabetic rats. <i>Journal of Functional Foods</i> , 2019 , 59, 1-7	5.1 2
377	Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. <i>Scientific Reports</i> , 2019 , 9, 6156	4.9 39

376	Predictive Value of Microdose Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1221-1236	6.2	6
375	Modification of Clinoptilolite with Benzalkonium Chloride as a Carrier of Metformin Hydrochloride. 2019 , 31, 1275-1278		
374	The evidence of metabolic-improving effect of metformin in Ay/a mice with genetically-induced melanocortin obesity and the contribution of hypothalamic mechanisms to this effect. 2019 , 14, e0213779		19
373	Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine. 2019 , 8, 396-406		16
372	Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia. 2019 , 14, e0214862		7
371	Association between Polymorphisms of and Metabolic Response to Metformin in Women with Polycystic Ovary Syndrome. 2019 , 20,		5
370	Sulfenamide derivatives can improve transporter-mediated cellular uptake of metformin and induce cytotoxicity in human breast adenocarcinoma cell lines. 2019 , 87, 321-334		13
369	Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1193-1203	6.2	30
368	Unraveling the complexity of complex mixtures by combining high-resolution pharmacological, analytical and spectroscopic techniques: antidiabetic constituents in Chinese medicinal plants. 2019 , 218, 202-218		7
367	Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. 2019 , 75, 809-816		3
366	Metformin prolongs lifespan through remodeling the energy distribution strategy in silkworm,. 2019 , 11, 240-248		21
365	The Association of Premorbid Metformin Exposure With Mortality and Organ Dysfunction in Sepsis: A Systematic Review and Meta-Analysis. 2019 , 1, e0009		5
364	LC-MS/MS method for simultaneous determination of rivaroxaban and metformin in rat plasma: application to pharmacokinetic interaction study. 2019 , 11, 2269-2281		2
363	Application of quantitative spectral deconvolution 1H NMR (qsd-NMR) in the simultaneous quantitative determination of creatinine and metformin in human urine. 2019 , 11, 5487-5499		4
362	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. 2019 , 19, 1133		9
361	Role of Metformin on Osteoblast Differentiation in Type 2 Diabetes. 2019 , 2019, 9203934		26
360	Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A randomised, crossover trial. 2019 , 7, e14307		10
359	Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited. 2019 , 59, 507-536		22

358	Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 730-737	6.1	6
357	Metformin: A Candidate Drug for Renal Diseases. 2018 , 20,		29
356	Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury. 2019 , 32, 297-306		10
355	Metformin; an old antidiabetic drug with new potentials in bone disorders. <i>Biomedicine and Pharmacotherapy</i> , 2019 , 109, 1593-1601	7.5	47
354	Modelling degradation kinetics of metformin and guanylyurea in soil microcosms to derive degradation end-points. 2019 , 245, 735-745		8
353	Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine. 2019 , 127, 282-290		11
352	Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice. 2019 , 140, 21-32		7
351	Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. 2019 , 42, 787-796		2
350	Acid-base and electrolyte disturbances in patients with diabetes mellitus. 2019 , 74, 28-33		4
349	High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells. <i>Biomolecules</i> , 2019 , 9,	5.9	28
348	No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. 2019 , 8, 818-826		2
347	SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. 2019 , 846, 23-29		20
346	Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects. 2019 , 8, 576-584		2
345	Environmental risk assessment of metformin and its transformation product guanylyurea. I. Environmental fate. 2019 , 216, 844-854		18
344	Pharmacological activation of dimethylarginine dimethylaminohydrolase (DDAH) activity by inorganic nitrate and DDAH inhibition by N-hydroxy-L-arginine, N,N-dimethyl-L-citrulline and N,N-dimethyl-N-hydroxy-L-citrulline: results and overview. 2019 , 51, 483-494		4
343	Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. 2019 , 35, e3109		34
342	A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. 2019 , 163, 153-161		21
341	Glyoxalase 1 Modulation in Obesity and Diabetes. 2019 , 30, 354-374		40

340	Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers. 2020 , 9, 107-114	3
339	Design, optimization, characterization, and evaluation of sterosomes as a carrier of metformin for treatment of lung cancer. 2020 , 30, 150-162	11
338	Metformin has a direct effect on ovarian cells that is dependent on organic cation transporters. 2020 , 499, 110591	7
337	Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". 2020 , 33, 9-35	38
336	Pharmacokinetics in children with chronic kidney disease. 2020 , 35, 1153-1172	2
335	Old wine in new bottles: Drug repurposing in oncology. 2020 , 866, 172784	32
334	An investigation on host-guest complexation of Metformin hydrochloride with hydroxypropyl- β -cyclodextrin for enhanced oral bioavailability. 2020 , 21, 514-518	2
333	Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. 2020 , 126, 354-362	16
332	A review of phenformin, metformin, and imeglimin. 2020 , 81, 390-401	24
331	Comparison of the gamma-Pareto convolution with conventional methods of characterising metformin pharmacokinetics in dogs. 2020 , 47, 19-45	4
330	Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin. 2020 , 174, 113787	20
329	Organic Cation Transporters in Health and Disease. 2020 , 72, 253-319	95
328	Analysis of urinary metabolic alteration in type 2 diabetic rats treated with metformin using the metabolomics of quantitative spectral deconvolution ¹ H NMR spectroscopy. 2020 , 153, 104513	7
327	Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer. 2020 , 19, 2490-2501	6
326	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 2020 , 98, S1-S115	251
325	A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy. 2020 , 19, 1559-1576	3
324	Oral Metformin and Polymetformin Reprogram Immunosuppressive Microenvironment and Boost Immune Checkpoint Inhibitor Therapy in Colorectal Cancer. 2020 , 3, 2000168	1
323	Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers. 2020 , 9, 910-917	2

322	Metformin and cardiorenal outcomes in diabetes: A reappraisal. 2020 , 22, 904-915		26
321	Inhibitory Action of Antidiabetic Drugs on the Free Radical Production by the Rod Outer Segment Ectopic Aerobic Metabolism. 2020 , 9,		4
320	Role of metformin in various pathologies: state-of-the-art microcapsules for improving its pharmacokinetics. 2020 , 11, 733-753		4
319	Polydimethylsiloxane-customized nanoplatform for delivery of antidiabetic drugs. 2020 , 11, 415-429		3
318	Metformin: A Prospective Alternative for the Treatment of Chronic Pain. 2020 , 11, 558474		7
317	Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus. 2020 , 99, e23212		1
316	Questions Regarding Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes. 2020 , 155, 1171-1172		1
315	Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. 2020 , 8, 509714		7
314	Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes. 2020 , 63, 2194-2204		5
313	Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes. 2020 , 2020, 9879517		0
312	Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus. 2020 , 13, 3873-3878		2
311	Successful Prediction of Positron Emission Tomography-Imaged Metformin Hepatic Uptake Clearance in Humans Using the Quantitative Proteomics-Informed Relative Expression Factor Approach. 2020 , 48, 1210-1216		6
310	Development and evaluation of controlled release of metformin hydrochloride for improving the oral bioavailability based on a novel enteric osmotic pump capsule. 2020 , 60, 102054		4
309	Metformin-associated lactic acidosis: reinforcing learning points. 2020 , 13,		2
308	Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells. <i>Cancers</i> , 2020 , 12,	6.6	10
307	Is metformin a geroprotector? A peek into the current clinical and experimental data. 2020 , 191, 111350		3
306	Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model. 2020 , 8,		4
305	The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition. 2020 , 21,		7

304	Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. <i>Clinical Drug Investigation</i> , 2020 , 40, 927-946	3.2	7
303	Metformin as a Potential Agent in the Treatment of Multiple Sclerosis. 2020 , 21,		9
302	A Study of Associations Between Plasma Metformin Concentration, Lactic Acidosis, and Mortality in an Emergency Hospitalization Context. 2020 , 48, e1194-e1202		7
301	Effects of Pregnancy on the Pharmacokinetics of Metformin. 2020 , 48, 264-271		15
300	Natural Products, Traditional Uses and Pharmacological Activities of the Genus (Biebersteiniaceae). 2020 , 9,		3
299	Metformin Biodistribution: A Key to Mechanisms of Action?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5
298	Orally hypoglycemic activity of an insulin mimetic glycoprotein isolated from <i>Cnidocolus quercifolius</i> Pohl. (Euphorbiaceae) seeds, Cq-IMP. 2020 , 159, 886-895		1
297	rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study. 2020 , 2020, 2975898		1
296	Development of a capillary electrophoresis-mass spectrometry method for the analysis of metformin and its transformation product guanylurea in biota. 2020 , 412, 4985-4996		0
295	Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm. 2020 , 15, e0234571		16
294	Metformin Suppresses Development of the <i>Echinococcus multilocularis</i> Larval Stage by Targeting the TOR Pathway. 2020 , 64,		4
293	Renal Trapping in Accidental Metformin Intoxication. 2020 , 5, 1525-1528		1
292	Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. 2020 , 98, 415-430		22
291	An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases. 2020 , 146, 1369-1375		4
290	Metformin is distributed to tumor tissue in breast cancer patients in vivo: A C-metformin PET/CT study. 2020 , 181, 107-113		2
289	Controlled Release of Highly Hydrophilic Drugs from Novel Poly(Magnesium Acrylate) Matrix Tablets. 2020 , 12,		5
288	The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. 2020 , 43, 948-955		38
287	Metformin Activity against Breast Cancer: Mechanistic Differences by Molecular Subtype and Metabolic Conditions. 2020 ,		2

286	Metformin and Micronutrient Status in Type 2 Diabetes: Does Polypharmacy Involving Acid-Suppressing Medications Affect Vitamin B12 Levels?. 2020 , 13, 2093-2108	9
285	Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. 2020 , 9,	2
284	The pharmacokinetics of metformin in patients receiving intermittent haemodialysis. 2020 , 86, 1430-1443	4
283	Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module. 2020 , 30, 1735-1752.e7	18
282	PPAR δ -Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice. <i>Molecules</i> , 2020 , 25,	4.8 6
281	Effect of exercise on key pharmacokinetic parameters related to metformin absorption in healthy humans: A pilot study. 2020 , 30, 858-864	2
280	The safety and pharmacokinetics of metformin in patients with chronic liver disease. 2020 , 51, 565-575	6
279	Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease. 2020 , 22, 1014-1023	4
278	Novel Metformin-Based Schiff Bases: Synthesis, Characterization, and Antibacterial Evaluation. 2020 , 13,	12
277	Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos. 2020 , 37, 1227-1238	0
276	A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad. 2020 , 30, 211-216	1
275	AMPK Activation by Metformin Promotes Survival of Dormant ER Breast Cancer Cells. 2020 , 26, 3707-3719	21
274	Phenformin Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice without Affecting Immune Cell Infiltration. 2020 , 12,	1
273	Synthesis and characterization of metformin-pluronic based polyurethanes for controlled drug delivery. 2021 , 70, 656-667	4
272	Metformin, Microbiome and Protection Against Colorectal Cancer. 2021 , 66, 1409-1414	10
271	Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects. 2021 , 10, 207-213	0
270	Assessment of the hypoglycemic effect of Bixin in alloxan-induced diabetic rats: and studies. 2021 , 39, 1017-1028	3
269	Synthesis of drug conjugated magnetic nanocomposite with enhanced hypoglycemic effects. 2021 , 120, 111697	4

268	In Vitro Dissolution and In Vivo Bioequivalence Evaluation of Two Metformin Extended-Release Tablets. 2021 , 10, 414-419	2
267	Metformin Preconditioning and Postconditioning to Reduce Ischemia Reperfusion Injury in an Isolated Ex Vivo Rat and Porcine Kidney Normothermic Machine Perfusion Model. 2021 , 14, 222-230	7
266	Synthesis, characterization and toxicity profiling of graphene oxide-metformin hydrogel as a sustained release system for metformin in-vitro. 2021 , 36, 769-774	1
265	Oral anti-diabetic drugs as endocrine disruptors in vitro - No evidence for additive effects in binary mixtures. 2021 , 70, 105007	
264	Ruthenium compounds as potential therapeutic agents for type 2 diabetes mellitus. 2021 , 213, 113064	4
263	The impact of chemical engineering and technological advances on managing diabetes: present and future concepts. 2021 , 50, 2102-2146	12
262	Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease. 2021 , 329, 1198-1209	19
261	Cellular and Molecular Mechanisms of Metformin Action. 2021 , 42, 77-96	70
260	Counterfeit formulations: analytical perspective on anorectics. 2021 , 39, 1-25	2
259	Plant Alkaloids with Antidiabetic Potential. 2021 , 251-266	
258	Metformin Preserves β Cell Compensation in Insulin Secretion and Mass Expansion in Prediabetic Nile Rats. 2021 , 22,	1
257	A New Understanding of Metformin. 2021 ,	0
256	The usefulness of measuring the anion gap in diagnosing metformin-associated lactic acidosis: a case series. 2021 , 15, 17	0
255	Case Study 7: Transporters Case Studies-In Vitro Solutions for Translatable Outcomes. 2021 , 2342, 709-735	
254	The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis. 2021 , 14, 563-572	0
253	Synthesis and Characterization of Lipophilic Salts of Metformin to Improve Its Repurposing for Cancer Therapy. 2021 , 6, 2626-2637	4
252	Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. 2021 , 19, 1618-1639	2
251	Drug-Drug Interactions at Organic Cation Transporter 1. 2021 , 12, 628705	5

250	Effect of berberine on hyperglycaemia and gut microbiota composition in type 2 diabetic Goto-Kakizaki rats. 2021 , 27, 708-724	11
249	Metformin doses to ensure efficacy and safety in patients with reduced kidney function. 2021 , 16, e0246247	0
248	The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus. 2021 , 22,	14
247	Metformin Strongly Affects Gut Microbiome Composition in High-Fat Diet-Induced Type 2 Diabetes Mouse Model of Both Sexes. 2021 , 12, 626359	8
246	Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study. 2021 , 8, 640785	5
245	Comparison of the performance of two grades of metformin hydrochloride elaboration by means of the SeDeM system, compressibility, compactability, and process capability indices. 2021 , 47, 484-497	0
244	Pharmacokinetics of metformin in collagen-induced arthritis rats. 2021 , 185, 114413	0
243	Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues. 2021 , 16, e0249594	4
242	From Pharmacogenetics to Gene Expression: Implications for Precision Medicine in Diabetes.	
241	Effect of metformin on biomarkers of placental-mediated disease: A systematic review and meta-analysis. 2021 , 107, 51-58	2
240	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. 2021 , 110, 1513-1526	1
239	A Bibliometrics Analysis of Metformin Development From 1980 to 2019. 2021 , 12, 645810	3
238	Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells. <i>Scientific Reports</i> , 2021 , 11, 10487	4.9 5
237	Republished: Metformin-associated lactic acidosis: reinforcing learning points. 2021 , 59, 124-127	0
236	Interfering with Metabolic Profile of Triple-Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. 2021 , 133, 13517-13525	0
235	Interfering with Metabolic Profile of Triple-Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. 2021 , 60, 13405-13413	10
234	A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators. 2021 , 13,	0
233	Incorporation of Sulfonamide Moiety into Biguanide Scaffold Results in Apoptosis Induction and Cell Cycle Arrest in MCF-7 Breast Cancer Cells. 2021 , 22,	1

232	Bilayer tablets with sustained-release metformin and immediate-release sitagliptin: preparation and in vitro/in vivo evaluation. 2021 , 51, 579-586		0
231	Rapamycin induced hyperglycemia is associated with exacerbated age-related osteoarthritis.		0
230	Cholinergic and metabolic effects of metformin in mouse brain. 2021 , 170, 211-217		2
229	Metformin in the era of new antidiabetics. 2021 , 17, 475-485		1
228	Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?. 2021 ,		0
227	Metformin derived carbon dots: Highly biocompatible fluorescent nanomaterials as mitochondrial targeting and blood-brain barrier penetrating biomarkers. 2021 , 592, 485-497		15
226	Why Should Metformin Not Be Given in Advanced Kidney Disease? Potential Leads from Computer Simulations. 2021 , 6, 15382-15391		1
225	Prevention of Hypertensive Disorders of Pregnancy-Is There a Place for Metformin?. 2021 , 10,		4
224	Mechanism and application of metformin in kidney diseases: An update. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 138, 111454	7.5	5
223	Undercover Toxic Mβage □Trois of Amylin, Copper (II) and Metformin in Human Embryonic Kidney Cells. 2021 , 13,		3
222	The Hormetic Effect of Metformin: "Less Is More"?. 2021 , 22,		5
221	Recent Perspective of Metformin. 2021 , 22, 85-90		1
220	Low metformin dose and its therapeutic serum concentration in prediabetes. <i>Scientific Reports</i> , 2021 , 11, 11684	4.9	3
219	Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
218	mPEG-PCL Polymeric Micelles Influence Pharmacokinetics and Hypoglycemic Efficacy of Metformin through Inhibition of Organic Cation Transporters in Rats. 2021 , 18, 2586-2599		0
217	Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke. <i>Life Sciences</i> , 2021 , 274, 119343	6.8	12
216	Metformin Protects against Radiation-Induced Acute Effects by Limiting Senescence of Bronchial-Epithelial Cells. 2021 , 22,		4
215	Novel deep learning-based transcriptome data analysis for drug-drug interaction prediction with an application in diabetes. 2021 , 22, 318		4

214	Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment. 2021 , 25, 1163-1172	0
213	Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model. 2021 , 12, 769-787	15
212	Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. 2021 , 13,	2
211	Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. 2021 , 2021, 1497449	39
210	Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit. 2021 , 12, 587801	12
209	Metformin Transport Rates Between Plasma and Red Blood Cells in Humans. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2
208	Quantitation of Plasma Membrane Drug Transporters in Kidney Tissue and Cell Lines Using a Novel Proteomic Approach Enabled a Prospective Prediction of Metformin Disposition. 2021 , 49, 938-946	0
207	Pharmacokinetics and Bioequivalence of a Generic Fixed-Dose Combination Tablet of Metformin Hydrochloride/Vildagliptin Versus a Branded Product in Healthy Chinese Subjects Under Fed and Fasting Conditions. 2021 ,	
206	Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters. 2021 , 13,	4
205	Valsartan in combination with metformin and gliclazide in diabetic rat model using developed RP-HPLC method. 2021 , 7,	0
204	Transcriptional Regulation of Isoforms and by Metformin and Simvastatin through Analyzing Nascent RNA Synthesis in a Human Brain Cell Line. <i>Biomolecules</i> , 2021 , 11,	5.9 2
203	Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?. <i>Biomolecules</i> , 2021 , 11,	5.9 2
202	Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: Essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77). 2021 , 100, 428-455	3
201	Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids. 2021 , 178, 108985	2
200	The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress and Tumor Growth. 2021 , 11, 690435	1
199	New complexes of metformin based on the copolymer of N-vinylpyrrolidone with triethylene glycol dimethacrylate and their activity in experimental type 2 diabetes mellitus. 2021 , 28, 1	0
198	Akut Brek Hasar Dlgusunda Metformin le Dkili Laktik Asidoz. 2021 , 5, 233-236	
197	A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan. 2021 , 12, 718942	17

196	Targeting Cardiovascular Risk Factors Through Dietary Adaptations and Caloric Restriction Mimetics. 2021 , 8, 758058		4
195	Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. 2021 ,		1
194	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. 2021 , 47, 101272		5
193	Can Metformin Downshift the Gears of Aging to Slow Emphysema Progression?. 2021 , 204, 621-622		
192	Clinically significant findings of high-risk mutations in human SLC29A4 gene associated with diabetes mellitus type 2 in Pakistani population. 2021 , 1-14		0
191	Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases. 2021 , 9,		1
190	NDMA analytics in metformin products: Comparison of methods and pitfalls. 2021 , 168, 106026		4
189	Combination of Metformin and Exercise in Management of Metabolic Abnormalities Observed in Type 2 Diabetes Mellitus. 2021 , 14, 4043-4057		1
188	Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. 2021 , 88, 941-952		4
187	Biguanides drugs: Past success stories and promising future for drug discovery. 2021 , 224, 113726		4
186	Metformin dampens cisplatin cytotoxicity on leukemia cells after incorporation into cubosomal nanoformulation. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 143, 112140	7.5	2
185	Efficient synthesis strategy of folate-modified carboxymethyl chitosan/CaCO hybrid nanospheres and their drug-carrying and sustained release properties. 2021 , 32, 799-812		2
184	Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells. <i>Scientific Reports</i> , 2021 , 11, 2529	4.9	17
183	Type 2 Diabetes Mellitus. 2021 ,		
182	Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?. 2020 , 2076, 1-30		5
181	Transporter-Mediated Drug-Drug Interactions and Their Significance. 2019 , 1141, 241-291		28
180	A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1419-1431	6.2	16
179	Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist. 2021 , 34, 1127-1135		7

178	Chapter 2:Barriers to Adopting Green Chemistry in Drug Discovery. 2015 , 13-38	2
177	Targeting liver stage malaria with metformin. 2019 , 4,	15
176	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. 2018 , 3,	44
175	Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner. 2014 , 9, e100525	68
174	[Proposal for the modification of metformin use in patients with chronic kidney disease]. 2012 , 153, 1527-35	1
173	Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. 2011 , 3, 1028-38	40
172	Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. 2018 , 10, 386-401	22
171	Metformin as a new anti-cancer drug in adrenocortical carcinoma. 2016 , 7, 49636-49648	30
170	Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer. 2017 , 8, 100113-100127	16
169	Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators. 2019 , 10, 3518-3532	8
168	Metabolic Effects of Metformin in Humans. 2019 , 15, 328-339	5
167	Do metformin a real anticarcinogen? A critical reappraisal of experimental data. 2014 , 2, 60	16
166	Metformin - For the dermatologist. 2016 , 48, 4-10	18
165	Hepatogenous Diabetes: An Underestimated Problem of Liver Cirrhosis. 2018 , 22, 552-559	15
164	Metformin versus insulin in the management of gestational diabetes mellitus. 2019 , 16, 346	1
163	Expert design and optimization of a novel buccoadhesive blend film impregnated with metformin nanoparticles. 2020 , 11, 573-590	3
162	Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus. 2012 , 02, 179-185	3
161	Comparative Pharmacokinetic Study between Metformin Alone and Combined with Orlistat in Healthy Mexican Volunteers. 2012 , 03, 300-306	2

160	Metformin Use and Metformin-associated Lactic Acidosis in Intensive Care Unit Patients with Diabetes. 2019 , 11, e4739	6
159	The Effects of Accelerated Temperature-Controlled Stability Systems on the Release Profile of Primary Bile Acid-Based Delivery Microcapsules. 2021 , 13,	2
158	Design of experiment-based LC-MS/MS method development for simultaneous estimation of nateglinide and metformin hydrochloride in rat plasma. 2021 , 56, e4789	1
157	Metformin anticipates peak of lactate during high-intensity interval training but no changes performance or neuromuscular response in amateur swimmers. 2021 , 46, 305-313	0
156	Case study 6. Transporter case studies: in vitro solutions for translatable outcomes. 2014 , 1113, 485-511	
155	Nierinsufficiëntie en medicatie. 2014 , 59-68	
154	CHAPTER 13:DrugDrug Interactions: Computational Approaches. 2015 , 283-308	
153	Evaluation of Sustained-release Dosage Form with Novel Metformin Salts. 2015 , 16, 7838-7843	2
152	Pharmacogenetics of hypoglycemic agents. 2015 , 18, 28-34	2
151	Supplements/Diet/Other Integrative Method Vernacular and Controversies from A to Z: What is the Latest or Greatest, or Not So Great?!. 2016 , 343-383	
150	Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region. 2016 , 19, 125-131	0
149	Metformin as Adjuvant Therapy in Ovarian and Endometrial Cancers. 2018 , 279-304	
148	Successful treatment of metformin-associated lactic acidosis in a hemodialysis patient. 2018 , 51, 395-399	
147	Comparison of the effects of metformin on MDA-MB-231 breast cancer cells in a monolayer culture and in tumour spheroids as a function of nutrient concentrations.	
146	STORIA NATURALE DELLA MALATTIA RENALE NEL DIABETE E TRATTAMENTO DELLIPERGLICEMIA NEI PAZIENTI CON DIABETE DI TIPO 2 E RIDOTTA FUNZIONE RENALE. 2019 , 3,	
145	A Case Report on Metformin-Associated Lactic Acidosis. 2020 , 12, e9533	
144	Estimating Heritability of Glycaemic Response to Metformin using Nationwide Electronic Health Records and Population-Sized Pedigree.	
143	Active mitochondrial respiration in cancer: a target for the drug. 2021 , 1	5

142	Metformin-induced lactic acidosis in critically ill patients. 2021 , 28, 502-503	
141	A fatal autopsy case of metformin-associated lactic acidosis and respiratory failure with proven high plasma metformin concentration. 2021 , 28, 532-536	
140	In vitro pH dependent passive transport of ketoprofen and metformin.. 2021 , 9, 57-68	1
139	Chemically modified chitosan for biomolecule delivery. 2022 , 501-518	1
138	Design and characterization of novel pulsatile delivery system of biguanide antidiabetic drug. 2020 , 12, 356-368	
137	Circadian Clock and Uptake Transporters. 2020 , 131-158	
136	AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells.	
135	Kinetics and Mechanism of Oxidation of Metformin Hydrochloride by Hexamolybdocobaltate(III) in Acidic Medium. 2020 , 33, 15-20	
134	A Unique Case of Metformin-associated Severe Lactic Acidosis Without Preexisting Renal Disease: Perspectives on Prolonged Dialysis and Education for Prevention. 2020 , 12, e7564	1
133	Metformin strongly affects gut microbiome composition in high-fat diet-induced type 2 diabetes mouse model of both sexes.	1
132	Metformin-associated lactic acidosis. 2020 , 66, 438-442	1
131	Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. 2012 , 17, 621-5	59
130	Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. 2014 , 139, 27-65	23
129	Patient profiling in diabetes and role of canagliflozin. 2014 , 7, 367-77	1
128	Metformin-clinical pharmacology in PCOs. 2015 , 8, 187-92	20
127	Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article. 2015 , 44, 176-84	2
126	Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis. 2015 , 2015, 26-30	2
125	Design and In-vitro Evaluation of Sustained Release Floating Tablets of Metformin HCl Based on Effervescence and Swelling. 2016 , 15, 53-70	2

124	Pharmacogenetic variation of gene and metformin response in type2 diabetes patients. 2017 , 6, 91-94	7
123	Application of a Pharmacokinetic Model of Metformin Clearance in a Population with Acute Myeloid Leukemia. 2018 , 7, 41-45	
122	The clinical application of metformin in children and adolescents: A short update. 2020 , 91, e2020086	1
121	Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes.. 2022 , 40, 97-107	1
120	Continuous use of metformin in patients receiving contrast medium: what is the evidence? A systematic review and meta-analysis. 2021 , 1	
119	Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway. 2021 , 1	3
118	Estimating heritability of glycaemic response to metformin using nationwide electronic health records and population-sized pedigree. 2021 , 1,	0
117	Effects of low-dose metformin on pre-frailty among middle-aged and elderly pre-diabetic people.	1
116	Multiple Transport Mechanisms Involved in the Intestinal Absorption of Metformin: Impact on the Nonlinear Absorption Kinetics: Contribution of Transporters to Metformin Absorption.. 2022 ,	0
115	Diabetes and Kidney disease: metformin. 2022 , 521-531	0
114	Review of pharmaceutical and therapeutic approaches for type 2 diabetes and related disorders.. 2022 ,	
113	Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions.. 2022 , 23,	0
112	Mitochondria as an important target of metformin: the mechanism of action, toxic and side effects, and new therapeutic applications.. 2022 , 106114	3
111	Deciphering metformin action in obese mice: A critical re-evaluation of established protocols.. <i>Metabolism: Clinical and Experimental</i> , 2021 , 154956	12.7 1
110	Blood-Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke.. 2022 , 23,	2
109	Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents with Obesity.. 2022 ,	1
108	Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives.. 2022 , 41, 53	0
107	Hexokinase-2-Linked Glycolytic Overload and Unscheduled Glycolysis-Driver of Insulin Resistance and Development of Vascular Complications of Diabetes.. 2022 , 23,	1

106	Low-dose metformin targets the lysosomal AMPK pathway through PEN2.. 2022 , 603, 159-165		19
105	Prescription Drugs and Mitochondrial Metabolism.. 2022 ,		0
104	Metformin Intervention-A Panacea for Cancer Treatment?. <i>Cancers</i> , 2022 , 14,	6.6	2
103	Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis.. 2022 ,		1
102	Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis.. 2022 , 119, e2122287119		4
101	Urinary excretion of metformin in diabetic patients with and without tuberculosis. 2022 ,		
100	The effect of metformin on bladder cancer incidence and outcomes ∅ systematic review and meta-analysis. 2022 , 1-18		0
99	Enhanced circulation longevity and pharmacodynamics of metformin from surface-modified nanostructured lipid carriers based on solidified reverse micellar solutions.. 2022 , 8, e09100		0
98	Let-7 underlies metformin-induced inhibition of hepatic glucose production.. 2022 , 119, e2122217119		1
97	Biological Properties of Transition Metal Complexes with Metformin and Its Analogues.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	1
96	Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K).. 2022 , 45, 382-393		0
95	Tamsulosin alters the pharmacokinetics of metformin via inhibition of renal multidrug and toxin extrusion protein 1 and organic cation transporter 2 in rats.. 2022 , 212, 114666		0
94	Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 149, 112844	7.5	2
93	A Review on Metformin: Clinical Significance and Side Effects. 2021 , 6179-6186		
92	Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges.. 2021 , 23,		4
91	Clinical Pharmacokinetics of Metformin.		
90	???1?(A case of intractable lactic acidosis associated with Metformin overdose). <i>Nihon Kyukyu Igakukai Zasshi</i> , 2021 , 32, 86-91		0
89	Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic). <i>BioMedInformatics</i> , 2022 , 2, 217-233		0

88	The effect of additional acarbose on metformin-associated artificially high F-Fluorodeoxyglucose uptake in positron emission tomography/computed tomography.. <i>Acta Diabetologica</i> , 2022 , 1	3.9	
87	Avoiding N-Nitrosodimethylamine Formation in Metformin Pharmaceuticals by Limiting Dimethylamine and Nitrite.. <i>International Journal of Pharmaceutics</i> , 2022 , 121740	6.5	0
86	Table_1.docx. 2018 ,		
85	Table_1.docx. 2019 ,		
84	Table_2.docx. 2019 ,		
83	Table_3.docx. 2019 ,		
82	Cross-species single-cell transcriptomic analysis reveals divergence of cell composition and functions in mammalian ileum epithelium.. <i>Cell Regeneration</i> , 2022 , 11, 19	2.5	0
81	The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial.. <i>Scientific Reports</i> , 2022 , 12, 7656	4.9	1
80	Antidiabetic activity and metabolite profiles of ascidian <i>Halocynthia roretzi</i> . <i>Journal of Functional Foods</i> , 2022 , 93, 105095	5.1	0
79	Metformin-associated Lactic Acidosis with Hypoglycemia during the COVID-19 Pandemic: A Case Report. <i>Internal Medicine</i> , 2022 ,	1.1	0
78	The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 151, 113130	7.5	
77	Metformin adsorption onto activated carbon prepared by acid activation and carbonization of orange peel. <i>International Journal of Phytoremediation</i> , 1-12	3.9	1
76	Challenges and Opportunities for Improved Drug-Drug Interaction Predictions for Renal OCT2 and MATE1 / 2-K Transporters. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	0
75	Metformin: Is it a drug for all reasons and diseases?. <i>Metabolism: Clinical and Experimental</i> , 2022 , 15522312.7	6	
74	Combined regimens of cisplatin and metformin in cancer therapy: A systematic review and meta-analysis. <i>Life Sciences</i> , 2022 , 120680	6.8	1
73	Ultra-Fast Measurement of Metformin in the Clinical Setting Using Probe Electrospray Ionization Mass spectrometry (PESI-MS). <i>Journal of Analytical Toxicology</i> ,	2.9	
72	Chemical screening of food-related chemicals for human fatty liver risk: Combining high content imaging of cellular responses with in vitro to in vivo extrapolation.		
71	Smart Nano-Actuators for Electrochemical Sensing of Metformin in Human Plasma. <i>SSRN Electronic Journal</i> ,	1	

70	Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> ,	5.6	
69	Stable-Isotope Dilution GCMS Measurement of Metformin in Human Serum and Urine after Derivatization with Pentafluoropropionic Anhydride and Its Application in Becker Muscular Dystrophy Patients Administered with Metformin, L-Citrulline, or Their Combination. <i>Molecules</i> , 2022 , <i>27</i> , 3850	4.8	1
68	Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study. <i>Biomolecules</i> , 2022 , <i>12</i> , 877	5.9	1
67	Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin. <i>Acta Pharmaceutica Sinica B</i> , 2022 ,	15.5	0
66	Free interstitial levels of metformin in the liver of healthy and diabetic Wistar rats. <i>Brazilian Journal of Pharmaceutical Sciences</i> , <i>58</i> ,	1.8	
65	Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. <i>Pharmaceuticals</i> , 2022 , <i>15</i> , 786	5.2	
64	The Mechanism of Action of Biguanides: New Answers to a Complex Question. <i>Cancers</i> , 2022 , <i>14</i> , 3220	6.6	2
63	Curcumin and metformin synergistically modulate peripheral and central immune mechanisms of pain. <i>Scientific Reports</i> , 2022 , <i>12</i> ,	4.9	0
62	A comparison of postoperative blood lactate concentrations and kinetics in cardiac surgical patients being and not being administered metformin. <i>Journal of Medical Science</i> , 2022 , <i>91</i> , e631	1.6	
61	Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> ,	3.6	
60	Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. <i>Clinical Drug Investigation</i> ,	3.2	
59	THERAPEUTIC USE OF METFORMIN IN THYROID CANCER. <i>Military Medical Science Letters (Vojenske Zdravotnicke Listy)</i> ,	0.2	
58	The effect of dietary fibers on the absorption of oral hypoglycemic drugs: a systematic review of controlled trials. <i>International Journal of Diabetes in Developing Countries</i> ,	0.8	
57	Relationship between Plasmatic Metformin Concentration and Renal Replacement Therapy: A Multicenter Cohort Study. 2022 , Publish Ahead of Print,		
56	The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response. 2022 , <i>17</i> , e0271410		
55	Phenformin Down-Regulates c-Myc Expression to Suppress the Expression of Pro-Inflammatory Cytokines in Keratinocytes. 2022 , <i>11</i> , 2429		
54	Metformin toxicity: A meta-summary of case reports. 2022 , <i>13</i> , 654-664		
53	Bioequivalence of China- and Germany-Manufactured Metformin Extended-Release Tablets Under Fed and Fasted Conditions in Healthy Volunteers: A Randomized, Open-Label, 2-Way Crossover Study.		

- 52 Formulation of a Gastroretentive In Situ Oral Gel Containing Metformin HCl Based on DoE. **2022**, 14, 1777 ○
- 51 Synergism between metformin and analgesics/vitamin B12 in a model of painful diabetic neuropathy. **2022**, 153, 113441 ○
- 50 Effect of metformin on intact mitochondria from liver and brain: Concept revisited. **2022**, 931, 175177 ○
- 49 The Use of Pregnancy Physiologically Based Pharmacokinetic Modeling for Renally Cleared Drugs. **2022**, 62, ○
- 48 Near-infrared phosphorescent cyclometalated platinum (II) and iridium (III) complexes with metformin moiety: Design and study towards anticancer theranostic agents. **2022**, 237, 111992 ○
- 47 Chapter 1. Chemical Approaches for Beta-cell Biology. **2022**, 1-52 ○
- 46 The effect of metformin on ameliorating neurological function deficits and tissue damage in rats following spinal cord injury: A systematic review and network meta-analysis. 16, ○
- 45 LCMS/MS Method Assay for Simultaneous Determination of the Apixaban and Metformin in Rat Plasma: Assessment of Pharmacokinetic Drug-Drug Interaction Study. ○
- 44 On the Verge of Precision Medicine in Diabetes. **2022**, 82, 1389-1401 ○
- 43 Transdermal Delivery of Metformin Utilizing Ionic Liquid Technology: Insight Into the Relationship Between Counterion Structures and Properties. ○
- 42 A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ○
- 41 The effect of Chinese herbal formulas combined with metformin on modulating the gut microbiota in the amelioration of type 2 diabetes mellitus: A systematic review and meta-analysis. 13, ○
- 40 An in silico Modeling for the Prediction of Metformin Interaction with Gadolinium-Based MR Contrast Agent. **2022**, 18, 1353-1358 ○
- 39 Use of Glucose-Lowering Agents in Diabetes and Chronic Kidney Disease. **2022**, ○
- 38 Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin. **2022**, 15, 1107-1117 ○
- 37 Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models. ○
- 36 The role of metformin as a treatment for neuropsychiatric illness. **2022**, 64, 32-43 ○
- 35 Plasma Therapeutic Drug Monitoring and Clinical Toxicology. **2022**, 21-42 ○

- 34 Oral Delivery of Kidney Targeting Nanotherapeutics for Polycystic Kidney Disease. ○
- 33 The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. **2022**, 4, 1369-1401 ○
- 32 Monitoring of Drug Release via Intra Body Communication with an Edible Pill. 2200731 ○
- 31 Metformin prevents hypoxia-induced podocyte injury by regulating the ZEB2 / TG2 axis. ○
- 30 Shouldn't Stage 4 And 5 Chronic Kidney Disease Patients Use Metformin?. ○
- 29 KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. **2022**, 102, S1-S127 8
- 28 Smart nano-actuators for electrochemical sensing of Metformin in human plasma. **2022**, 132928 ○
- 27 A blast from the past: To tame time with metformin. **2022**, 208, 111743 ○
- 26 Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review). **2022**, 49, ○
- 25 Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects. ○
- 24 Metformin: new applications for an old drug. **2022**, ○
- 23 Drug repurposing: Metformin's effect against liver tissue damage in diabetes and prostate cancer model. ○
- 22 Determination of equilibria constants of arginine:glycine amidinotransferase (AGAT)-catalyzed reactions using concentrations of circulating amino acids. 1
- 21 Fluorinated triphenylphosphonium analogs improve cell selectivity and in vivo detection of mito-metformin. **2022**, 25, 105670 ○
- 20 Preparation and characterization of self-emulsifying drug delivery system (SEDDS) for enhancing oral bioavailability of metformin hydrochloride using hydrophobic ion pairing complexation. 1-21 ○
- 19 Metformin Attenuates Hyperglycaemia-Stimulated Pro-Fibrotic Gene Expression in Adventitial Fibroblasts via Inhibition of Discoidin Domain Receptor 2. **2023**, 24, 585 ○
- 18 Metformin. **2023**, 71-88 ○
- 17 Microbially produced vitamin B12 contributes to the lipid-lowering effect of silymarin. **2023**, 14, ○

- 16 Metabolic and Metabolomic Effects of Metformin in Murine Model of Pulmonary Adenoma Formation. 1-14
- 15 Co-drug development of gallic acid and metformin targeting the pro-inflammatory cytokines for the treatment of breast cancer.
- 14 Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review. 13,
- 13 Novel Strategies for Metformin as an Anti-aging Drug in Skin Aging. **2023**, 99-116
- 12 Netrin-1 Monoclonal Antibody-Functionalized Nanoparticle Loaded with Metformin Prevents the Progression of Abdominal Aortic Aneurysms. Volume 18, 627-639
- 11 Effect of Pre-Meal Metformin With or Without an Acute Exercise Bout on Postprandial Lipemic and Glycemic Responses in Metabolic Syndrome Patients: A Randomized, Open Label, Crossover Study. **2023**, 28, 107424842311563
- 10 Anti-inflammatory therapy of atherosclerosis: focusing on IKK **2023**, 20,
- 9 Toxicokinetics of metformin overdose treated with CVVHDF. **2023**,
- 8 Significant impact of time-of-day variation on metformin pharmacokinetics.
- 7 Metformin mitigates radiation toxicity exerting antioxidant and genoprotective properties.
- 6 Advances in natural small molecules on pretranslational regulation of gluconeogenesis.
- 5 Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects. **2023**, 31, 59
- 4 Predictors of Metformin Side Effects in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
- 3 Applications of metformin in dentistry A review. **2023**,
- 2 Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. **2023**,
- 1 Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. **2023**, 163, 114754